ZentraBio™ SLU-PP-332 – 60 X 250 mcg

Description

SLU-PP-332 (Research Material) — 60 × 250 mcg Capsules

SLU-PP-332 is an experimental, non-peptide small molecule supplied by ZentraBio for advanced metabolic and mitochondrial research. In preclinical research contexts, SLU-PP-332 has been studied in relation to cellular energy pathways, including mechanisms associated with mitochondrial activity, oxidative capacity, and energy utilization. No medical, nutritional, or performance-related use has been established.

Unlike peptide- or hormone-based compounds, SLU-PP-332 is a synthetic small molecule, provided in capsule format to support consistent unit handling and laboratory reproducibility. This makes it a suitable research material for controlled laboratory environments conducting analytical work, method development, or reference studies related to mitochondrial and metabolic biology.

ZentraBio supplies SLU-PP-332 in precisely dosed capsules, manufactured to high purity standards and accompanied by clear research-use-only labeling and batch traceability. Each container includes 60 capsules, each containing 250 mcg of active material, corresponding to a total active material content of 15 mg. Reported purity is ≥99.88%.

SLU-PP-332 is part of ZentraBio’s broader portfolio of research-grade metabolic compounds, developed for professional research settings where consistency, documentation, and presentation are essential.

---

Key Product Details

• Material type: Small molecule (non-peptide)

• Form: Capsules

• Quantity: 60 capsules × 250 mcg

• Total active material: 15 mg

• Purity: ≥99.88%

• Excipients: cellulose, gelatin, magnesium stearate, silica

• Storage: Store tightly closed at 15–25 °C; protect from moisture and light

• Safety & handling: Use standard laboratory PPE; dispose of material in accordance with chemical-waste guidelines

---

Regulatory / Intended Use Notice

This product is supplied strictly for authorised laboratory research purposes (e.g. analytical testing, method development, reference work).
NOT FOR HUMAN OR VETERINARY USE.
Not approved as a medicinal product, food supplement, cosmetic ingredient, or food additive.
Keep out of reach of children.

---

Educational Overview (science-based, non-use framing)

What SLU-PP-332 is in the literature

In published research, SLU-PP-332 is characterized as a synthetic ERR (estrogen-related receptor) agonist intended as a research tool to probe aerobic metabolism, mitochondrial function, and exercise-adaptation biology. [1]
It has been discussed in preclinical contexts as part of the broader “exercise-mimetic” research area—not as a proven therapy or established human intervention. [1][2]

Important correction vs common online claims: SLU-PP-332 is generally described as targeting ERRα/β/γ, not as a primary PPARδ agonist in the core publications describing the molecule. [1][2]

---

Mechanistic biology (why ERR agonism matters in metabolism research)

ERRs (ERRα/β/γ) are nuclear receptors involved in regulating gene programs linked to:

• Mitochondrial oxidative metabolism and cellular respiration (mitochondrial function is a central readout in SLU-PP-332 studies). [1]
• Aerobic/exercise-associated transcriptional programs in skeletal muscle (used experimentally to model aspects of an “acute aerobic exercise response”). [1]
• Energy expenditure and fatty-acid oxidation pathways in preclinical metabolic models. [2]

Because ERRs operate at the level of gene-expression programs, the research interest is often framed around system-wide metabolic adaptation signals rather than short-lived “stimulant-like” effects. [1][2]

---

Research Highlights (preclinical; not established for humans)

Skeletal muscle, respiration, and endurance-related readouts (preclinical)

In an ACS Chemical Biology publication describing SLU-PP-332:

• SLU-PP-332 increased mitochondrial function and cellular respiration in a skeletal muscle cell line. [1]
• In mice, SLU-PP-332 increased type IIa oxidative skeletal muscle fibers and enhanced exercise endurance, and the “exercise program” effects were reported as ERRα-dependent for the endurance phenotype. [1]

Obesity / metabolic syndrome models (preclinical)

A 2024 Journal of Pharmacology and Experimental Therapeutics paper reports that, in mouse models of obesity/metabolic syndrome:

• SLU-PP-332 administration was associated with increased energy expenditure and fatty-acid oxidation and reduced fat mass accumulation in those models. [2]
• The authors report improvements consistent with better insulin sensitivity in models of metabolic syndrome (again, in mice). [2]

Aging kidney mitochondrial dysfunction & inflammation (preclinical)

In a 2023 American Journal of Pathology paper on aging kidneys:

• ERRs were reported as decreased in aging human and mouse kidneys, and the study used SLU-PP-332 as a pan-ERR agonist in aged mice. [3]
• The authors report reversal of multiple aging-associated kidney readouts after treatment in aged mice, including markers related to mitochondrial dysfunction and inflammatory cytokines, with discussion involving pathways such as cGAS–STING and STAT3 signaling. [3]

---

What this does not mean

• These findings do not establish that SLU-PP-332 is safe or effective for humans, and they do not constitute medical guidance. The cited papers are preclinical and mechanistic research contexts. [1][2][3]
• “Capsule format” here is about research handling and unit consistency, not a claim about real-world bioavailability, human dosing, or any intended ingestion pathway.

---

Regulatory / Intended Use Notice

This product is supplied strictly for authorised laboratory research purposes (e.g., analytical testing, method development, reference work).
NOT FOR HUMAN OR VETERINARY USE.
Not approved as a medicinal product, food supplement, cosmetic ingredient, or food additive.
Keep out of reach of children.

---

References (clickable where possible)

1. Billon C, et al. “Synthetic ERRα/β/γ Agonist Induces an ERRα-Dependent Acute Aerobic Exercise Response and Enhances Exercise Capacity.” ACS Chemical Biology (2023). DOI: 10.1021/acschembio.2c00720 — https://doi.org/10.1021/acschembio.2c00720
2. Billon C, et al. “A Synthetic ERR Agonist Alleviates Metabolic Syndrome.” Journal of Pharmacology and Experimental Therapeutics (2024). DOI: 10.1124/jpet.123.001733 — https://doi.org/10.1124/jpet.123.001733
3. Wang XX, et al. “Estrogen-Related Receptor Agonism Reverses Mitochondrial Dysfunction and Inflammation in the Aging Kidney.” American Journal of Pathology (2023). DOI: 10.1016/j.ajpath.2023.07.008 — https://doi.org/10.1016/j.ajpath.2023.07.008